AbstractImmune‐mediated regression of melanocytic neoplasms is predominantly lymphocytic, driven by CD8+ anti‐tumoral T‐cells and, rarely, natural killer cells. Histopathologic features of regression include effacement of the epidermis, replacement of tumor cells by a fibrotic stroma, varying degrees of chronic inflammation (usually lymphocytes) and melanophages, as well as vascular ectasia and angioplasia. The understanding of regression and the complex immune response in melanoma has led to the development of targeted immunotherapy in melanoma. Here, we report a case of near‐complete regression of a melanocytic neoplasm associated with neutrophilic and eosinophilic inflammation, suggesting a non‐traditional pathway of regression that has yet to be explored.

More from our Archive

• DOI: 10.1093/bjd/ljad072 2023

  Malignancy risk in patients with atopic dermatitis: a population-based cohort study

  Joy Wan, Daniel B Shin, Maha N Syed, Katrina Abuabara, Adina R Lemeshow, Zelma C Chiesa Fuxench, Joel M Gelfand

• DOI: 10.1111/myc.13626 2023

  <i>Candida auris</i> from colonisation to candidemia: A four‐year study

  Juan Vicente Mulet Bayona, Nuria Tormo Palop, Carme Salvador García, María del Remedio Guna Serrano, Concepción Gimeno Cardona

• DOI: 10.1111/jocd.15872 2023

  Efficacy of combined treatment with human adipose tissue stem cell‐derived exosome‐containing solution and microneedling for facial skin aging: A 12‐week prospective, randomized, split‐face study

  Gyeong‐Hun Park, Hyuck Hoon Kwon, Joon Seok, Steven Hoseong Yang, Joon Lee, Byung Chul Park, Eun Shin, Kui Young Park

• DOI: 10.1093/bjd/ljad240 2023

  Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

  Stephan Weidinger, Thomas Bieber, Michael J Cork, Adam Reich, Rosamund Wilson, Sonia Quaratino, Marisa Stebegg, Nuala Brennan, Sally Gilbert, John T O’Malley, Ben Porter-Brown

• DOI: 10.1111/iwj.14311 2023

  Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation

  Yuqing Du, Jie Wang, Weijing Fan, Renyan Huang, Hongfei Wang, Guobin Liu

• DOI: 10.1001/jamadermatol.2023.2008 2023

  Understanding Discordant Perceptions of Disease Severity Between Physicians and Patients With Eczema and Psoriasis Using Structural Equation Modeling

  Valencia Long, Zhaojin Chen, Ruochen Du, Yiong Huak Chan, Yik Weng Yew, Hazel H. Oon, Steven Thng, Nur Qasrina Binte Iskandar Lim, Chris Tan, Nisha Suyien Chandran, Jose M. Valderas, Phillip Phan, Ellie Choi

• DOI: 10.1093/bjd/ljad224 2023

  Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?

  Carlo Alberto Maronese, John R Ingram, Angelo V Marzano

• DOI: 10.1093/sexmed/qfad030 2023

  Self-reported reasons for having difficulty reaching orgasm in men with diverse etiologies

  David L Rowland, Sarah Padilla, Zsuzsanna Kӧvi, Krisztina Hevesi

• DOI: 10.1093/ced/llad227 2023

  ChatGPT and dermatology: friends or foes?

  Luca Potestio, Fabrizio Martora, Alessia Villani, Angelo Ruggiero, Massimiliano Scalvenzi, Matteo Megna

• DOI: 10.1111/pde.15378 2023

  Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the <scp>ALLEGRO</scp> phase 2b/3 randomized, double‐blind, placebo‐controlled trial

  Maria Hordinsky, Adelaide A. Hebert, Melinda Gooderham, Ohsang Kwon, Nikolay Murashkin, Hong Fang, Kazutoshi Harada, Ernest Law, Dalia Wajsbrot, Liza Takiya, Samuel H. Zwillich, Robert Wolk, Helen Tran